scholarly journals Angiographic dynamics of coronary flow state after percutaneous coronary intervention in carriers of polymorphic RS1800470 variants of the TGF-β1 gene

2019 ◽  
pp. 77-82
Author(s):  
D. A. Brusentsov ◽  
S. Yu. Nikulina ◽  
P. A. Shesternya
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Venous Blood ◽  
Coronary Intervention ◽  
Flow State ◽  
Gensini Score ◽  
Mean Values ◽  
Caucasian Race ◽  
Percutaneous Coronary

Aim. To study the relationship between the angiographic dynamics of the state of the coronary bed in patients undergoing percutaneous coronary intervention (PCI) due to myocardial infarction (MI) and the carriage of polymorphic rs1800470 variants of the transforming growth factor beta-1 gene (TGF-β1).Material and methods. The study included 89 men with MI of the Caucasian race aged 32 to 65 years (52 [45,0-58,0]). Genomic deoxyribonucleic acid (DNA) was extracted from venous blood by phenol-chloroform technique. The rs1800470 polymorphism of the TGF-β1 gene was tested using real-time polymerase chain reaction (PCR) (TaqMan probes, AB 7900HT). Assessment of the severity of coronary lesions was carried out initially according to the standard coronary angiography (CAG) protocol with the calculation of the Gensini score. CAG was also conducted in the dynamics after 5-103 months (42,3±29,5 months) of the study beginning.Results. In male carriers of the rs1800470 A allele of the TGF-β1 gene, the mean values of the Gensini score statistically significantly increased (47,5±34,1 (CAG-1) and 64,5±35,5 (CAG-2), p <0,001) in comparison with carriers of the homozygous GG rs1800470 variant of the TGF-β1 gene (43,5±21,1 (CAG-1) and 46,2±23,2 (CAG2), p=0,066). In patients who had rs1800470 A allele of the TGF-β1 gene, a 20%decrease in the Gensini score was observed after 7 months (p=0,013), and 30% — after 5 months (p=0,003) of the initial CAG. The development of late stent restenoses in carriers of the rs1800470 A allele and the homozygous risk genotype AA of the TGF-β1 gene was noted at an earlier date — 8 (p=0,047) and 12 months (p=0,002), respectively.Conclusion. Currently, the conduct of CAG in dynamics in patients undergoing PCI is recommended as clinically indicated. The exception is the group of patients who underwent endoprosthesis replacement of the left coronary artery or have uncorrected stenosis of a different location from 3 to 12 months after PCI. The presented data show a possible predictor role of rG1800470 polymorphism of the TGF-β1 gene in relation to the progression of coronary atherosclerosis and the development of late stent restenoses.

Abstract 3167: Serum Activin A Level Is Associated With Infarct Size In Patients With Acute Myocardial Infarction Who Undergo Successful Primary Percutaneous Coronary Intervention

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Toru Miyoshi ◽  
Satoshi Hirohata ◽  
Tadahisa Uesugi ◽  
Minoru Hirota ◽  
Hiromichi Ohnishi ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Infarct Size ◽  
Primary Percutaneous Coronary Intervention ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Coronary Intervention ◽  
Activin A ◽  
St Segment Elevation ◽  
Percutaneous Coronary

PURPOSE: Activin A, a member of the transforming growth factor-beta cytokine family, has been suggested to play a role in inflammation and have pleiotropic functions. We examined the alteration of serum activin A level in patients with ST-segment elevation myocardial infarction (STEMI) who received successful primary percutaneous coronary intervention (PCI) within 12 hours, and investigated whether serum activin A was associated with infarct size. METHODS: We examined 26 patients with STEMI, 20 consecutive stable angina pectoris (AP) patients and 20 normal subjects. In STEMI patients, blood samples were collected before PCI (day0) and days 1, 2, 7 and 14. Serum activin A level was measured by enzyme-linked immunoassay. Change of activin A between day 2 and day0 (delta 2d) was also examined. The serum levels of activin A were compared with infarct size, as indicated with peak CK. RESULTS: Patients with STEMI demonstrated significantly higher serum activin A level (before PCI) than control subjects and patients with AP (316±112, 369±153 and 569±272 pg/ml, p<0.001 and p=0.007, respectively). The activin A level was significantly elevated and peaked on day 0 and reduced on days 2, and then gradually increased until days 14. Log-transformed peak CK was significantly correlated with serum activin A level on day0 (r=0.55, p=0.004) and delta 2d (r=0.58, p=0.023). In stepwise analysis, serum activin A level (beta=0.37, p=0.022) as well as age, culprit lesion (LAD) and smoking was an independent predictor of peak CK. CONCLUSIONS: The findings suggest that serum activin A level was elevated in STEMI and it may be associated with infarct size in STEMI patients.

Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarc-tion Patients with Primary Percutaneous Coronary Intervention

2020 ◽  
Vol 21 ◽  
Author(s):  
Bo Zhao ◽  
Guang Ping Li ◽  
Jian Jun Peng ◽  
Li Hui Ren ◽  
Li Cheng Lei ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
Primary Pci ◽  
Gensini Score ◽  
St Segment Elevation ◽  
St Segment ◽  
Percutaneous Coronary ◽  
One Year

Objective: ST-segment elevation myocardial infarction (STEMI) patients with the multivessel disease have distinctive plaque characteristics in non-IRA lesions. Intensive statin therapy was a potential approach to treat STEMI patients with the non-IRA disease. However, there is still poor evidence about the therapeutic effect. In this study, we have evaluated the detailed therapeutic effect of statin plus ezetimibe intensive therapy. Method: For STEMI patients with non-IRA disease undergoing primary percutaneous coronary intervention (PCI), 183 control STEMI patients without non-IRA disease undergoing primary PCI, and 200 STEMI patients with non-IRA disease undergoing primary PCI were introduced into this study. 200 STEMI patients with non-IRA disease undergoing primary PCI were divided into Normal group, Intensive group, Normal & Combined group, and Intensive & Combined group. The baseline information for each participant was recorded. Meanwhile, the physiological and biochemical indicators of each member with different treatments were collected after one-year follow-up. Result: For STEMI patients with non-IRA disease undergoing primary PCI, no differences could be detected in multiple indexes such as OCT examination results, age, stroke, etc. However, diabetes mellitus, smoking, and coronary Gensini score were different between different groups (P<0.05). After one year follow-up, cholesterol, low-density lipoprotein, coronary Gensini score, thin-cap fibroatheroma, length of non-infarcted arterial lesions, non-infarct artery lesion range, myocardial infarction again, and revascularization again were significantly different between different groups (P<0.05). Conclusion: The results mentioned above suggested that pitavastatin combined with ezetimibe was an effective approach to STEMI patients with non-IRA disease undergoing primary PCI. The results obtained in this study have provided a novel way for the treatment of STEMI patients with non-IRA disease undergoing primary PCI.

Markers of oxidative stress in acute myocardial infarction treated by percutaneous coronary intervention

Open Medicine ◽  
2009 ◽  
Vol 4 (1) ◽  
pp. 26-31 ◽  
Author(s):  
Eva Sedláková ◽  
Oliver Rácz ◽  
Eva Lovásová ◽  
Roman Beòaèka ◽  
Martin Kurpas ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Venous Blood ◽  
Plasma Lipid ◽  
Coronary Intervention ◽  
Control Group ◽  
Coronary Syndrome ◽  
Percutaneous Coronary

AbstractIn the current study, we evaluated the dynamics of oxidative stress markers in patients with acute myocardial infarction (AMI) treated by primary percutaneous coronary intervention (PCI). Thirty consecutive patients with AMI with ST elevation were included. Plasma lipid peroxidation end product malondialdehyde (MDA) and total antioxidant capacity (TAC) in blood plasma were evaluated. Peripheral venous blood samples were obtained prior to reperfusion and at five time points after reperfusion. The control group consisted of 20 ischemic patients without acute coronary syndrome. TAC in the AMI group at admission was lower than in control patients (1.26 + 0.32 vs. 1.52 + 0.24 mmol/l). Within 1 h after reperfusion, in most cases, values significantly declined (1 min, 1.10 + 0.33 mmol/l; 1 h, 1.06 + 0.21 mmol/l [p= 0.03]). After 3 h, values began to increase (1.14 + 0.29 mmol/l) and returned to basal values after 3 d (1.29 + 0.24 mmol/l). MDA levels in AMI patients at admission were higher than in control patients (1.66 + 0.55 vs. 1.44 + 0.55 mmol/l) but showed a sustained decrease over the 3 h after reperfusion of the occluded artery (1 min, 1.57 + 0.37 mmol/l; 1 h, 1.50 + 0.35 μmol/l; 3 h, 1.35 + 0.59 μmol/l [p = 0.03]). Reperfusion of the occluded coronary artery by PCI in AMI lead to an immediate decrease in TAC, suggesting formation of reactive oxygen species. However, the MDA level significantly decreased after reperfusion. This may suggests less reperfusion injury after PCI.

scholarly journals Correlation between monocyte to high-density lipoprotein ratio and major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention

2021 ◽  
Vol 37 (3) ◽  
Author(s):  
Rong Yu ◽  
Ruigang Hou ◽  
Tong Wang ◽  
Tianliang Li ◽  
Huiyuan Han ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
High Density Lipoprotein ◽  
Cardiovascular Events ◽  
Density Lipoprotein ◽  
Coronary Intervention ◽  
High Density ◽  
Major Adverse Cardiovascular Events ◽  
Gensini Score ◽  
Coronary Syndrome ◽  
Percutaneous Coronary

Objective: To investigate the correlation between monocyte to high-density lipoprotein ratio (MHR) and major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods: In this retrospective study, 120 ACS patients who received PCI in our hospital from September 2014 to August 2019 were selected and divided into MACE group and normal discharge (ND) group. Their clinical data were collected, and MHR values were compared. Logistic regression analysis was conducted to analyze the correlations between various factors and ACS. The correlation between MHR and Gensini score was subjected to Pearson’s analysis. Receiver operating characteristic (ROC) curve was plotted to analyze the diagnostic value of MHR for MACE. Results: Hypertension degree, white cell count, Gensini score, MHR and the levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC), apolipoprotein A1 (ApoA1), ApoB, lipoprotein (a) [LP(a)] and uric acid (UA) in MACE group were significantly higher than those in ND group (P<0.05). HDLC, ApoA1, TC, MHR, LDLC and ApoB were independent risk factors for MACE of ACS patients after PCI (P<0.05). There was a positive correlation between MHR and Gensini score (r=0.832, P<0.05), and the optimal cutoff value of MHR for diagnosing MACE was 9.45. Conclusion: Serum MHR is positively correlated with Gensini score in ACS patients after PCI, which can be used as an independent predictor for MACE in hospital. doi: https://doi.org/10.12669/pjms.37.3.3469 How to cite this:Yu R, Hou R, Wang T, Li T, Han H, An J. Correlation between monocyte to high-density lipoprotein ratio and major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention. Pak J Med Sci. 2021;37(3):---------. doi: https://doi.org/10.12669/pjms.37.3.3469 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals New Opportunities for Determining the Terms of Carrying out the Control Coronarangiography after Percutaneous Coronary Intervention

2020 ◽  
Vol 5 (4) ◽  
pp. 51-59
Author(s):  
D. A. Brusentsov ◽  
P. A. Shesternya
Keyword(s):  
Coronary Heart Disease ◽  
Percutaneous Coronary Intervention ◽  
Heart Disease ◽  
Coronary Artery ◽  
Coronary Angiography ◽  
Coronary Intervention ◽  
Economic Damage ◽  
Gensini Score ◽  
Percutaneous Coronary ◽  
Tgf Β1

Background. Coronary heart disease is the leading cause of death in the Russian Federation, causing social and economic damage to the state. Previously published studies showed the association of rs1800470 polymorphism of the gene of the transforming growth factor-β1 (TGF-β1) with the risk of developing coronary artery disease due to more severe atherosclerotic lesions of the coronary arteries. Aim of the research. To study the association of single-nucleotide polymorphism rs1800470 of the TGF-β1 gene with the rate of progression of atherosclerotic coronary artery lesion. Material and methods. The study included 89 men with myocardial infarction, a Caucasian race under the age of 65 years (51 ± 7.9). Genomic DNA was isolated from venous blood by the phenol-chloroform method. The rs1800470 polymorphism of the TGF-β1 gene was tested using real-time polymerase chain reaction (PCR) (TaqMan probes, AB 7900HT). Assessment of the severity of coronary lesion was carried out initially according to the standard polyprojection coronary angiography protocol with the Gensini score calculated, as well as in dynamics after 40.7 ± 29.7 months (from 5 to 103 months). Results. Carrier of the rs1800470 allele A of the TGF-β1 gene is an independent risk factor for coronary heart disease and is associated with a more aggressive course of coronary atherosclerosis in men: a 20 % worsening of the Gensini score was observed after 7 months (p = 0.013), and by 30 % after 5 months (p = 0.003) from the initial coronary angiography. In addition, the homozygous genotype AA rs1800470 of the TGF-β1 gene is associated with the development of late stent restenoses in this group of patients after 12 months of observation (p = 0.002). Conclusion. Identification of carriers of the rs1800470 allele A of the TGF-β1 gene can help identify patients at risk for more rapid progression of coronary artery atherosclerosis in order to conduct angiographic control in the early period – 6 months from the initial percutaneous coronary intervention.

Sign in / Sign up

Export Citation Format

Share Document